Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema

European Journal of Ophthalmology

Volumn 18, Issue 3, 2008, Pages 469-472

  Montero, Javier A ^a,b   Ruiz Moreno, J M ^b,c   De La Vega, C ^b  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b Retina Unit ^*  (Spain)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Diabetic macular edema; Pegaptanib; Posterior hyaloid detachment

Indexed keywords

PEGAPTANIB;

AGED; ARTICLE; CASE REPORT; DIABETIC MACULAR EDEMA; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HUMAN; INFORMED CONSENT; INTERVENTION STUDY; LASER COAGULATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT FAILURE; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

EID: 54749108307     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210801800328     Document Type: Article

References (5)

1. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473-80.
2. Cunningham ET, Jr., Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-57.
3. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695 e1-15.
4. Arevalo JF, Fromow-Guerra J, Ouiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007; 114: 743-50.
5. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 68-73.